Boston Cell Standards developed a new diagnostic laboratory technology platform that, for the first time, enables the creation of measurement standards in an already-existing $2B laboratory testing market called “immunohistochemistry”. The value proposition is a quantum-level improvement in measurement accuracy and reproducibility in cancer biopsy testing, leading to a ten-fold reduction in lab errors and new diagnostic opportunities in oncology.